- Home
- NMZ vs COGT Comparison
NMZ vs COGT Comparison
Compare NMZ & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMZ
- COGT
- Stock Information
- Founded
- NMZ 2003
- COGT 2014
- Country
- NMZ United States
- COGT United States
- Employees
- NMZ N/A
- COGT N/A
- Industry
- NMZ Finance/Investors Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- NMZ Finance
- COGT Health Care
- Exchange
- NMZ Nasdaq
- COGT Nasdaq
- Market Cap
- NMZ 1.2B
- COGT 1.1B
- IPO Year
- NMZ N/A
- COGT 2018
- Fundamental
- Price
- NMZ $10.48
- COGT $12.33
- Analyst Decision
- NMZ
- COGT Strong Buy
- Analyst Count
- NMZ 0
- COGT 11
- Target Price
- NMZ N/A
- COGT $21.20
- AVG Volume (30 Days)
- NMZ 356.8K
- COGT 1.8M
- Earning Date
- NMZ 01-01-0001
- COGT 11-11-2025
- Dividend Yield
- NMZ 5.08%
- COGT N/A
- EPS Growth
- NMZ N/A
- COGT N/A
- EPS
- NMZ N/A
- COGT N/A
- Revenue
- NMZ N/A
- COGT N/A
- Revenue This Year
- NMZ N/A
- COGT N/A
- Revenue Next Year
- NMZ N/A
- COGT N/A
- P/E Ratio
- NMZ N/A
- COGT N/A
- Revenue Growth
- NMZ N/A
- COGT N/A
- 52 Week Low
- NMZ $8.26
- COGT $3.72
- 52 Week High
- NMZ $11.14
- COGT $13.50
- Technical
- Relative Strength Index (RSI)
- NMZ 59.60
- COGT 51.33
- Support Level
- NMZ $10.54
- COGT $12.31
- Resistance Level
- NMZ $10.66
- COGT $12.86
- Average True Range (ATR)
- NMZ 0.09
- COGT 0.55
- MACD
- NMZ 0.02
- COGT -0.11
- Stochastic Oscillator
- NMZ 71.89
- COGT 37.83
About NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share
Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The company's investment objectives is to provide current income exempt from regular federal income tax by investing predominantly in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories. It seeks to provide attractive monthly tax-free income, portfolio diversification and attractive after tax total returns. The fund invests in municipal securities that are exempt from federal income taxes.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.